Dexamethasone treatment was not noninferior with respect to functional outcomes and was associated with more complications
Adjusted hazard ratio remained elevated even 25 years after diagnosis, corresponding to one additional stroke per 93 IBD patients
Cumulative hazard of relapses higher among patients treated with rituximab versus ocrelizumab